Thomas G. Martin, MD

Cornell University, B.A., 1985, Genetics
University of Connecticut School of Medicine, M.D., 1989, Medicine
Harbor-UCLA Medical Center, 1992, Internal Medicine
University of California, San Francisco, 1996, Hematology and Oncology

• 1996-1999
  Assistant Adjunct Professor, Hematology/Oncology and Bone Marrow Transplant, University of California San Francisco, San Francisco, CA
• 1999-2001
  Assistant Professor of Medicine, Department of Blood and Marrow Transplantation, Division of Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX
• 2001-2003
  Director, Matched Unrelated Donor Program, Adult Leukemia and Bone Marrow Transplantation, University of California, CA
• 2001-2003
  Assistant Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
• 2003-2008
  Associate Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
• 2004
  Associate Director, Myeloma Clinic, Adult Ambulatory Care Clinic, University of California, San Francisco, CA.
• 2006
  Member, Committee on Human Research (CHR), University of California, San Francisco, CA.
• 2007
  Clinical Director, Adult Stem Cell Transplantation, Univ. University of California, San Francisco, CA.

• 1984
  Cornell Tradition Fellow Award
• 1989
  LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT
• 2003
  Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA

• Malchoff CD, Javier EC, Malchoff DM, Martin T, et al: Primary Cortisol Resistance Presenting as Isosexual Precocity. Journal of Endocrinology and Metabolism. 70:2, 503-9, 1990.
• Meng, YG, Martin T, Peterson ML, Shuman M, Cohen RL, Wong W: Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. British Journal of Haematology. 95: 535-541, 1996
• Martin TG, Somberg K, Cohen RL, Shuman MA, Meng YG: Thrombopoietin levels in cirrhotic patients before and after orthotopic liver transplantation. Annals of Internal Medicine. 127:4, 285-288, 1997.
• Martin, TG and Shuman, M.A; Interferon-Induced Thrombocytopenia: Is It Time for Thrombopoietin? Hepatology. 28:5, 1430-1432, 1998.
• Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin, RE, Korbling M; A comparative study of once-daily versus twice daily filgrastim administration for the mobilization and collection of CD34(+) peripheral blood progenitor cells in normal donors. British Journal of Hematology. 109, 770-772, 2000.
• Martin, TG and Gajewski JA: Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America. 15:1 97-120, 2001.
• Martin, TG and Linker, CA: Autologous Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America. 15:1 21- 143, 2001
• Shimoni A, Gajewski J, Donato M, Martin T, O'Brien S, Huh V, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S: Long-Term Follow-up of Recipients of CD8-depleted Donor Lymphocyte Infusions fro the Treatment of Chronic Myelogenous Leukemia Relapsing After Allogeneic Progenitor Cell Transplantation. Biology of Blood and Marrow Transplantation. 7:568-575, 2001
• Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin T, Ueno NT, Champlin RE, Khouri IF: Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Annals of Oncology. 13:450-459, 2002
• Thall PF, Inoue LYT and Martin TG: Adaptive Decision Making in a Lymphocyte Infusion Trial. Biometrics. 58:560-568, 2002
• Martin TG, Giralt S, Khouri I, Champlin RE: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia. Acute Leukemias IX. Hematology and Blood Transfusion. 41:483-484, 2003
• Gunn N, Damon L, Varosy P, Navarro W, Martin T, Reis C, Linker C. High CD34 Cell Dose Promotes Faster Platelet Recovery After Autologous Stem Cell Transplantation for Acute Myeloid Leukemia. Biol Blood Marrow Trasplant, 10:643-8, 2003
• Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M: Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 102(8):3052-9, 2003
• Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M: Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 17(12):2538-40, 2003
• Couriel DR, Saliba R, Hicks K, Ippoliti C, De Lima MJ, Hosing C, Khouri I, Andersson B, Donato M, Gajewski J, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R: Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. Blood 2004 Aug 1;104(3):649-54.
• Damon L, Rugo H, Tolaney S, Navarro W, Martin T 3rd, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar;12(3):316-24.
• Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep;38(6):421-6.
• de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb;22(2):258-64.
• Damon L, Damon LE, Gaensler K, Kaplan L, Martin T 3rd, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57.
• Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R and Linker C. Voriconazole is Safe and Effective as Prophylaxis for Early and Late Fungal Infections Following Allogeneic Hematopoietic Stem Cell Transplantation. Trans Infectious Disease, May 2009